Electromed Resultados de beneficios anteriores
Pasado controles de criterios 6/6
Electromed ha aumentado sus beneficios a una tasa media anual de 33.8%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 13.6% anual. Los ingresos han ido creciendo a una tasa media de 14.5% al año. La rentabilidad financiera de Electromed es de 20.6%, y sus márgenes netos son de 14.1%.
Información clave
33.84%
Tasa de crecimiento de los beneficios
34.24%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 8.90% |
| Tasa de crecimiento de los ingresos | 14.54% |
| Rentabilidad financiera | 20.55% |
| Margen neto | 14.08% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
ELMD: Refined Discount Rate And P/E Assumptions Will Drive Future Upside
Analysts raised their price target on Electromed by $2, reflecting updated assumptions about the discount rate, profit margin, revenue growth, and future P/E that support a slightly higher valuation framework. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rate and future P/E that leave room for upside if execution stays on track.ELMD: Refreshed Discount Rate And P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Electromed by $2, citing updated assumptions about discount rates, revenue growth, profit margins and future P/E that support a slightly higher fair value estimate. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rates and future P/E, which together suggest more support for the current valuation than before.
ELMD: Share Repurchases And Margin Execution Will Support Future Upside
Analysts have raised their price target on Electromed by $2 to reflect updated assumptions around revenue growth, profit margin and long-term P/E expectations. Analyst Commentary Recent research points to a more cautious tone around Electromed, even alongside the higher price target.ELMD: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have increased their price target on Electromed by $2 to $36, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as key factors behind the change. Analyst Commentary While the new US$36 price target reflects updated valuation work, some bearish analysts are still flagging risk factors that they believe limit upside for Electromed at current levels.ELMD: Share Repurchases Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target on Electromed up by $1 to $37, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E after the latest Street research. Analyst Commentary Recent Street research has focused on how Electromed's fundamentals line up with the revised fair value assumptions and the updated $37 target.ELMD: Completed Share Buyback Will Support Future Upside In Undervalued Shares
Analysts have adjusted their price target on Electromed to reflect a fair value of $36.00, citing only minor tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E. Their overall valuation view remains largely unchanged.ELMD: Share Buyback And Higher Margin Outlook Will Support Future Upside
Analysts have kept their price target for Electromed steady at US$34.00, reflecting updated views on slightly higher projected revenue growth and profit margins, along with a marginally adjusted discount rate and future P/E assumption. What's in the News Completed the repurchase of 40,848 shares, representing 0.49% of the company, for US$1 million under the share buyback announced on September 9, 2025 (Key Developments).ELMD: Higher Margin Outlook And Share Buyback Will Support Upside Potential
Analysts have raised their fair value estimate for Electromed from US$29 to US$34, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Between September 9, 2025 and September 30, 2025, Electromed repurchased 40,848 shares for US$1 million, representing 0.49% of shares.ELMD: Share Repurchase Program Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target for Electromed slightly higher to approximately $36.00 per share, citing modest improvements in discount rate assumptions and forward valuation metrics while largely reaffirming their prior outlook. What's in the News Completed a share repurchase tranche totaling 40,848 shares, or about 0.49 percent of outstanding shares, for approximately $1 million under the buyback program announced September 9, 2025 (company filing) Valuation Changes Fair Value Estimate reaffirmed at approximately $36.00 per share, reflecting no material change in intrinsic value assumptions.ELMD: Share Repurchase Plan And Expanding Outlook Will Lift Share Price
Analysts have raised their price target for Electromed from $35.25 to $36.00. They cite an improved outlook for future revenue growth, despite a slightly higher discount rate and marginally lower profit margin projections.ELMD: Double-Digit Revenue Gains And Buybacks Will Drive Shares Higher
Electromed's analyst fair value target increased slightly from $35.00 to $35.25, as analysts cite consistent double-digit revenue growth forecasts and improving operational efficiency in recent reports. Analyst Commentary Bullish Takeaways Bullish analysts highlight Electromed's consistent double-digit revenue growth forecasts and note that ongoing top-line expansion is expected in the coming years.
The Triple Down On Bronchiectasis Campaign Will Expand SmartVest Clearway's Market Reach
Diversifying beyond homecare and investing in sales efforts may drive revenue growth and improve earnings through expanded market channels and effective sales execution.Desglose de ingresos y gastos
Cómo gana y gasta dinero Electromed. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 72 | 10 | 42 | 1 |
| 31 Dec 25 | 69 | 9 | 41 | 1 |
| 30 Sep 25 | 66 | 8 | 40 | 1 |
| 30 Jun 25 | 64 | 8 | 39 | 1 |
| 31 Mar 25 | 61 | 7 | 38 | 1 |
| 31 Dec 24 | 60 | 7 | 36 | 1 |
| 30 Sep 24 | 57 | 6 | 35 | 1 |
| 30 Jun 24 | 55 | 5 | 34 | 1 |
| 31 Mar 24 | 53 | 4 | 34 | 1 |
| 31 Dec 23 | 52 | 4 | 34 | 1 |
| 30 Sep 23 | 50 | 3 | 33 | 1 |
| 30 Jun 23 | 48 | 3 | 32 | 1 |
| 31 Mar 23 | 46 | 3 | 30 | 1 |
| 31 Dec 22 | 44 | 2 | 29 | 1 |
| 30 Sep 22 | 42 | 2 | 28 | 1 |
| 30 Jun 22 | 42 | 2 | 27 | 1 |
| 31 Mar 22 | 40 | 2 | 26 | 1 |
| 31 Dec 21 | 39 | 2 | 25 | 1 |
| 30 Sep 21 | 38 | 2 | 24 | 2 |
| 30 Jun 21 | 36 | 2 | 22 | 2 |
| 31 Mar 21 | 33 | 3 | 21 | 2 |
| 31 Dec 20 | 33 | 4 | 21 | 2 |
| 30 Sep 20 | 32 | 4 | 20 | 1 |
| 30 Jun 20 | 32 | 4 | 20 | 1 |
| 31 Mar 20 | 34 | 4 | 20 | 1 |
| 31 Dec 19 | 33 | 4 | 20 | 1 |
| 30 Sep 19 | 32 | 3 | 20 | 1 |
| 30 Jun 19 | 31 | 2 | 20 | 1 |
| 31 Mar 19 | 31 | 2 | 20 | 1 |
| 31 Dec 18 | 30 | 2 | 20 | 0 |
| 30 Sep 18 | 29 | 2 | 20 | 0 |
| 30 Jun 18 | 28 | 2 | 19 | 0 |
| 31 Mar 18 | 28 | 2 | 18 | 0 |
| 31 Dec 17 | 27 | 2 | 18 | 0 |
| 30 Sep 17 | 27 | 2 | 17 | 0 |
| 30 Jun 17 | 26 | 2 | 16 | 1 |
| 31 Mar 17 | 24 | 2 | 16 | 1 |
| 31 Dec 16 | 24 | 1 | 15 | 1 |
| 30 Sep 16 | 23 | 2 | 15 | 1 |
| 30 Jun 16 | 23 | 2 | 14 | 0 |
| 31 Mar 16 | 22 | 2 | 14 | 0 |
| 31 Dec 15 | 21 | 2 | 13 | 0 |
| 30 Sep 15 | 20 | 1 | 12 | 0 |
| 30 Jun 15 | 19 | 1 | 12 | 0 |
Ingresos de calidad: ELMD tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (14.1%) de ELMD son superiores a los del año pasado (11.7%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: En los últimos 5 años, los beneficios de lELMD han crecido significativamente en un 33.8% al año.
Acelerando crecimiento: El crecimiento de los beneficios de ELMD en el último año (41.1%) supera su media de 5 años (33.8% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de ELMD en el último año (41.1%) superó al de la industria Medical Equipment 14.8%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (20.6%) de ELMD se considera alta.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 22:29 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Electromed, Inc. está cubierta por 6 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Ilya Zubkov | Freedom Broker |